Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Deferring treatment in hairy cell leukemia: is active surveillance safe?

Victoria M. Rogness, Xuefei Jia, Wei Wei, Brian T. Hill

Blood Neoplasia (2025) 2 (4): 100139.

https://doi.org/10.1016/j.bneo.2025.100139

Published: 2025

Journal Articles

Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence

Pin Lu, Carrie A Franzen, Aldana Vistarop, Andrey Efimov, SK Abrar Shahriyar, Shengchun Wang, Shilpa Rao, Marcus Messmer, Shazia Nakhoda, Edna Cukierman, Shuo Ma, Janusz Franco-Barraza, Juehua Gao, Y. Lynn Wang

Blood Neoplasia (2025) 2 (4): 100142.

https://doi.org/10.1016/j.bneo.2025.100142

Published: 2025

Includes: Multimedia, Supplemental data

Journal Articles

Eμ-TCL1 mice with conditional human BCL2 knockin as novel B-cell lymphoma model for studying venetoclax effects in vivo

Ismini Halmer, Daniela Asslaber, Laura Beckmann, Gero Knittel, Hans Christian Reinhardt, Hamid Kashkar, Michael Hallek, Jens Löber, Björn Chapuy, Alexander Egle, Günter Krause, Alexandra da Palma Guerreiro, Lukas P. Frenzel

Blood Neoplasia (2025) 2 (4): 100143.

https://doi.org/10.1016/j.bneo.2025.100143

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition

Ritul Sharma, Chunfen Zhang, Ravi Shah, Melanie M. Frigault, Amy J. Johnson, David Spencer Mangum, Luke D. Maese, Norman J. Lacayo, Aru Narendran

Blood Neoplasia (2025) 2 (4): 100148.

https://doi.org/10.1016/j.bneo.2025.100148

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma

Yoshito Nishimura, Yiqun Han, Nadia Toumeh, Guneet Janda, Yu Fujiwara, Urshila Durani, Grzegorz S. Nowakowski, Jonas Paludo, Stephen M. Ansell, Jithma P. Abeykoon

Blood Neoplasia (2025) 2 (3): 100134.

https://doi.org/10.1016/j.bneo.2025.100134

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study

Trine Trab, Iman Chanchiri, Ahmed Ludvigsen Al-Mashhadi, Emma Berggren Dall, Stine Rasch, Mette Johansen, Simon Husby, Mikkel Runason Simonsen, Michael Roost Clausen, Thomas Stauffer Larsen, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Mats Jerkeman, Christian Bjørn Poulsen, Laura Mors Haunstrup, Peter Brown, Tarec Christoffer El-Galaly, Kirsten Grønbæk

Blood Neoplasia (2025) 2 (3): 100128.

https://doi.org/10.1016/j.bneo.2025.100128

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world performance of the CALGB 10403 regimen in young adults in the United States

Brandon DaSilva, Alicia Darwin, Amy Zhang, Rutu D. Vyas, Kathryn Russell, Jason S. Gilbert, Virginia Tan, Susan Feldt, Hannah Johnston, Emily C. Liang, Adam S. DuVall, Michaela Liedtke, Wendy Stock, Ryan D. Cassaday, Marc Schwartz, Jessica T. Leonard, Lori S. Muffly, Marlise R. Luskin

Blood Neoplasia (2025) 2 (3): 100111.

https://doi.org/10.1016/j.bneo.2025.100111

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis

Inna Y. Gong, Michael Crump, Anca Prica, Andrew Calzavara, Ning Liu, Tiana Kordbacheh, Danielle Rodin, David Hodgson, Lee Mozessohn, Matthew C. Cheung, John Kuruvilla

Blood Neoplasia (2025) 2 (3): 100117.

https://doi.org/10.1016/j.bneo.2025.100117

Published: 2025

Includes: Supplemental data

Journal Articles

An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia

Peter M. Gordon, Robin L. Williams, Jason Ostergaard, Keegan C. Lee, Hannah N. Bui, Joseph M. Muretta, Bridget S. Wilson, Thomas Beder, Claudia D. Baldus, Luke Lambert, Benjamin E. Deonovic, Timothy Singleton, Sarah K. Tasian, Stuart S. Winter

Blood Neoplasia (2025) 2 (3): 100120.

https://doi.org/10.1016/j.bneo.2025.100120

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

Frederique St-Pierre, Stephen M. Broski, Zequn Sun, Masha Kocherginsky, Betsy LaPlant, Matthew J. Maurer, Andrew Quon, Lucia Baratto, Hatice Savas, Lale Kostakoglu, Jane N. Winter, Thomas E. Witzig, Brad Kahl, Andrew M. Evens, Leo I. Gordon

Blood Neoplasia (2025) 2 (3): 100113.

https://doi.org/10.1016/j.bneo.2025.100113

Published: 2025

Includes: Supplemental data

Journal Articles

Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain

Elias Lagonik, Elyse C. Page, John B. Bruning, Laura N. Eadie, Susan L. Heatley, Matthew Greenwood, Chun Y. Fong, Andrew S. Moore, David T. Yeung, Timothy P. Hughes, Deborah L. White

Blood Neoplasia (2025) 2 (3): 100109.

https://doi.org/10.1016/j.bneo.2025.100109

Published: 2025

Includes: Supplemental data

Journal Articles

Temporal clonal relatedness between myeloid neoplasm and nodal T-follicular helper cell lymphoma: a retrospective study

Mingfei Yan, Robert Stuver, Kai Shiang Lin, William T. Johnson, Steven M. Horwitz, Ahmet Dogan, Wenbin Xiao

Blood Neoplasia (2025) 2 (3): 100112.

https://doi.org/10.1016/j.bneo.2025.100112

Published: 2025

Includes: Supplemental data

Journal Articles

A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma

Yuan Xiao Zhu, Soumya Dutta, Gregory J. Ahmann, Laura Bruins, Mariano Arribas, Xianfeng Chen, Abhigna Polavarapu, Jonathan Chapman, Isaac Lopez, Marta Chesi, P. Leif Bergsagel, Abhishek Singharoy, Rafael Fonseca, Lisa M. Rimsza

Blood Neoplasia (2025) 2 (3): 100099.

https://doi.org/10.1016/j.bneo.2025.100099

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma

Nikita K. Dave, Veronica Carvajal, Alex C. Watts, Jordan S. Carter, Michael Cook, Colin Thomas, Donald E. Tsai, Stephen J. Schuster, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Wei-Ting Hwang, Daniel J. Landsburg, Sunita D. Nasta

Blood Neoplasia (2025) 2 (3): 100102.

https://doi.org/10.1016/j.bneo.2025.100102

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma

Edvan de Queiroz Crusoé, Joanna Suzana Leal Ribeiro dos Santos, Juliana de Andrade Santos, Herbert Henrique de Melo Santos, Allan de Souza Santos, Larissa Ferreira Lucas, Cristiane Almeida Requião de Pinna, Paula Nogueira Caldas Freire, Adriano Araujo de Jesus, Alessandro de Moura Almeida, Daniela Dourado Dutra, Marcos Fonseca Chaves, Jamile Souza Nicanor, Marco Aurelio Salvino, Maria da Gloria Bomfim Arruda, Vania Hungria

Blood Neoplasia (2025) 2 (3): 100081.

https://doi.org/10.1016/j.bneo.2025.100081

Published: 2025

Includes: Supplemental data

Journal Articles

Ambroxol induces myeloma cell death by inhibiting autophagy

Yutaka Hattori, Hiromu Sugiyama, Yamato Miyashita, Shinsuke Shibata, Taiga Okaue, Yoshinao Matsumoto, Taketo Yamada, Tomofumi Yamamoto, Takashi Yamaguchi, Kohei Yamazaki, Hisako Kunieda, Hideyuki Saya, Maiko Matsushita

Blood Neoplasia (2025) 2 (3): 100100.

https://doi.org/10.1016/j.bneo.2025.100100

Published: 2025

Includes: Supplemental data

Journal Articles

Magnetic resonance spectroscopy–based detection of response to therapy targeting glutaminolysis in lymphoma

Kavindra Nath, Pradeep K. Gupta, Shengchun Wang, Alexander A. Shestov, Neil Sen, Shilpa Rao, Stepan Orlovskiy, Cosimo Lobello, David Rushmore, Fernando Arias-Mendoza, Johnvesly Basappa, David S. Nelson, Mariusz A. Wasik

Blood Neoplasia (2025) 2 (3): 100105.

https://doi.org/10.1016/j.bneo.2025.100105

Published: 2025

Includes: Supplemental data

Journal Articles

Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies

Emil Ramsø Kyvsgaard, Trine Lønbo Grantzau, Mia Dahl Sørensen, Michael Boe Møller, Lene Dissing Sjø, Morten Grauslund, Trine Trab, Linea Cecilie Melchior, Lærke Sloth Andersen, Caroline Riley, Carsten U. Niemann, Jacob Haaber, Thomas Stauffer Larsen, Michael Roost Clausen, Kirsten Grønbæk, Martin Hutchings, Simon Husby

Blood Neoplasia (2025) 2 (3): 100096.

https://doi.org/10.1016/j.bneo.2025.100096

Published: 2025

Includes: Supplemental data

Journal Articles

Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience

Blood Neoplasia (2025) 2 (3): 100103.

https://doi.org/10.1016/j.bneo.2025.100103

Published: 2025

Journal Articles

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

Aaron S. Rosenberg, Emanual Maverakis, Caitlin Costello, Elizabeth A. Brem, Matthew Joseph Wieduwilt, Guillaume Luxardi, Paul Kaesberg, Keon Abedi, Samantha Herbert, Joseph Tuscano

Blood Neoplasia (2025) 2 (3): 100067.

https://doi.org/10.1016/j.bneo.2025.100067

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Deferring treatment in hairy cell leukemia: is active surveillance safe?

Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence

Eμ-TCL1 mice with conditional human BCL2 knockin as novel B-cell lymphoma model for studying venetoclax effects in vivo

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition

Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study

Real-world performance of the CALGB 10403 regimen in young adults in the United States

Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis

An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia

Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain

Temporal clonal relatedness between myeloid neoplasm and nodal T-follicular helper cell lymphoma: a retrospective study

A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma

Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma

Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma

Ambroxol induces myeloma cell death by inhibiting autophagy

Magnetic resonance spectroscopy–based detection of response to therapy targeting glutaminolysis in lymphoma

Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies

Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only